Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India

Co-Diagnostics, Inc. (Nasdaq: CODX), a pioneer in molecular diagnostics, announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has been selected to participate in the 2nd Advanced TB Diagnostics Course from December 15-19, 2025, at the ICMR–National Institute for Research in Tuberculosis (NIRT) in Chennai, India. This remarkable capacity-building workshop caters to Southeast Asian countries and is hosted by ICMR-NIRT in collaboration with the McGill International TB Centre and several global health organizations.

The workshop aims to enhance tuberculosis (TB) detection and research, featuring a diverse array of participants, including leading experts, national TB programs, diagnostics developers, and industry partners. During the five-day event, attendees will engage in sessions that traverse the entire diagnostics value chain. The curriculum will spotlight innovative technologies, cost-effectiveness modeling, evidence-based policy development, and practical strategies aimed at reducing the TB case-finding gap within Southeast Asia.

Prominent faculty members will lead presentations and panel discussions, with insights from reputable organizations such as the World Health Organization (WHO), The Gates Foundation, and FIND, alongside representatives from central TB institutions in India. Participants will also witness technology pitches from industry innovators unveiling emerging solutions in the diagnostics landscape.

Co-Diagnostics, through its cutting-edge, patented platform, continues to impact molecular diagnostics positively. The company's proprietary technology is harnessed to design specific tests for its Co-Dx PCR at-home and point-of-care platform (pending regulatory approval) to detect genetic markers used in various applications beyond infectious diseases. This venture into TB diagnostics underscores the importance of collaborative efforts in addressing global health challenges and improving health outcomes across the region.

Co-Diagnostics Inc. (Nasdaq: CODX) has made significant strides in the molecular diagnostics space, particularly with its joint venture, CoSara Diagnostics Pvt. Ltd. This partnership's recent invitation to participate in the 2nd Advanced TB Diagnostics Course in Chennai, India, underscores the increasing relevance of Co-Dx’s innovative diagnostics technologies in combating tuberculosis (TB) in South-East Asia.

As the region grapples with high TB prevalence, the need for sophisticated diagnostic solutions is pronounced. CoSara’s involvement in this multi-faceted workshop not only positions it at the forefront of TB diagnostics but also enhances its reputation among key stakeholders, including entities like WHO and the Gates Foundation. With the course focusing on emerging technologies, cost-effectiveness modeling, and practical strategies for case-finding, CoSara stands to benefit from invaluable insights and collaborations that may leverage its diagnostics capabilities.

Investors should take note of Co-Diagnostics’ strategic initiatives as they highlight its commitment to addressing pressing public health challenges. The company’s unique, patented platform is a competitive advantage, particularly as the global demand for accurate and timely diagnostic solutions rises, fueled by the lessons learned during the COVID-19 pandemic.

Moreover, participation in this workshop may attract attention from potential partners and clients looking for cutting-edge diagnostic technologies, likely translating into future business opportunities. As Co-Diagnostics continues to position itself as a leader in molecular diagnostics, its stock may offer growth potential in the mid to long term.

In summary, investors should consider the implications of CoSara’s participation in the TB Diagnostics Course as a positive signal, reflecting both the company's innovative capacity and its strategic alignment with global health initiatives. An investment in Co-Diagnostics could yield favorable returns as the company continues to expand its market footprint.